WestGold Metals has agreed to sell its option to acquire the Isoneva gold property in Finland to Jesmond Capital, marking a strategic shift to focus solely on North American exploration projects. The deal includes cash payments and shares in Jesmond, allowing WestGold to recover much of its investment while removing future funding obligations for Isoneva. WestGold will now concentrate on advancing its Idaho portfolio, including preparing for its first drill program. Jesmond will take over further exploration at Isoneva, benefiting from WestGold's retained stake in Jesmond shares.
WestGold Metals is the subject of this update. For readers following Basic Materials, here is Pluang's market snapshot as of Sep 15, 2026 18:12 WIB: 19 of 32 priced US stocks rose and 13 fell. Notable prices include APD at USD 285.43 (-0.59%), AU at USD 101.06 (+0.58%), and ICL at USD 5.48 (-0.54%).
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
